IM Cannabis ( ) - 株価, ニュースと分析Nasdaq:IMCC

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

IMCC 株式概要

IM Cannabis Corp.は、イスラエルとドイツで医療用大麻製品の育種、栽培、供給を行っている。

IMCC ファンダメンタル分析
スノーフレーク・スコア
評価	5/6
将来の成長	2/6
過去の実績	0/6
財務の健全性	3/6
配当金	0/6

報酬

当社が推定した公正価値より97.5%で取引されている

収益は年間15.94%増加すると予測されています

同業他社や業界と比較して、良好な取引価格

リスク分析

過去3か月間の株価の変動は非常に激しい

意味のある時価総額がありません ( $9M )

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

IM Cannabis Corp. 競合他社

Allied

OTCPK:ALID

US$5.3m

NovaBay Pharmaceuticals

NYSEAM:NBY

US$3.6m

Biofrontera

NasdaqCM:BFRI

US$6.4m

Pulmatrix

NasdaqCM:PULM

US$7.6m

価格と性能

の歴代最高値、変動、値下がりまとめIM Cannabis
過去の株価
現在の株価	CA$2.27
52週高値	CA$8.10
52週安値	CA$1.13
ベータ	1.68
11ヶ月の変化	-3.40%
3ヶ月変化	-9.71%
1年変化	-43.52%
33年間の変化	-98.85%
5年間の変化	n/a
IPOからの変化	-98.15%

Recent updates

IM Cannabis Shareholder Rafael Gabay raises stake

Sep 08

IM Cannabis GAAP EPS of -C$0.30, revenue of C$23.8M

Aug 15

IM Cannabis receives non-compliance notification from Nasdaq for minimum bid price requirement

Jul 19

cbdMD And IM Cannabis Partner To Sell CBD Products In Israeli Markets

Aug 14

IM Cannabis proposes public offering of securities

May 05

IM Cannabis acquires Israel's largest retail and online pharmacy business from Panaxia

Apr 30

株主還元

	IMCC	US Pharmaceuticals	US 市場
7D	1.8%	-0.1%	0.3%
1Y	-43.5%	19.0%	32.4%

業界別リターン: IMCC過去 1 年間で25.6 % の収益を上げたUS Pharmaceuticals業界を下回りました。

リターン対市場: IMCCは、過去 1 年間で22.8 % のリターンを上げたUS市場を下回りました。

価格変動

Is IMCC's price volatile compared to industry and market?
IMCC volatility
IMCC Average Weekly Movement	17.0%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

安定した株価: IMCCの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: IMCCの weekly volatility ( 24% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2008	95	Oren Shuster	imcannabis.com

IM Cannabis Corp.はイスラエルとドイツで医療用大麻製品の育種、栽培、供給を行っている。IMC、BLKMT、WAGNERS、LOT420のブランドで、医療用大麻のドライフラワーや、フルスペクトラムの系統別大麻エキスを提供している。同社は医療患者にサービスを提供している。IM Cannabis Corp.は2008年に設立され、イスラエルのテルアビブに本社を置いている。

IM Cannabis Corp. 基礎のまとめ

IM Cannabis の収益と売上を時価総額と比較するとどうか。
IMCC 基礎統計学
時価総額	US$4.93m
収益（TTM）	-US$10.38m
売上高(TTM)	US$36.75m

0.1x

P/Sレシオ

-0.5x

PER（株価収益率

IMCC は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
IMCC 損益計算書（TTM）
収益	CA$49.88m
売上原価	CA$43.77m
売上総利益	CA$6.11m
その他の費用	CA$20.20m
収益	-CA$14.09m

直近の収益報告

Jun 30, 2024

次回決算日

該当なし

一株当たり利益（EPS）	-6.31
グロス・マージン	12.25%
純利益率	-28.25%
有利子負債／自己資本比率	276.4%

IMCC の長期的なパフォーマンスは？

過去の実績と比較を見る

IMCC 株式概要

報酬

リスク分析

IM Cannabis Corp. 競合他社

OTCPK:ALID

US$5.3m

NYSEAM:NBY

US$3.6m

NasdaqCM:BFRI

US$6.4m

NasdaqCM:PULM

US$7.6m

価格と性能

最新ニュース

IM Cannabis Corp. announced that it expects to receive $1.613 million in funding

IM Cannabis Corp. Appoints Shmulik Arbel to Board of Directors

IM Cannabis Corp. announced that it has received CAD 2.091977 million in funding

First quarter 2024 earnings released: CA$0.42 loss per share (vs CA$0.027 profit in 1Q 2023)

IM Cannabis Corp. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings: EPS misses analyst expectations

Recent updates

IM Cannabis Corp. announced that it expects to receive $1.613 million in funding

IM Cannabis Corp. Appoints Shmulik Arbel to Board of Directors

IM Cannabis Corp. announced that it has received CAD 2.091977 million in funding

First quarter 2024 earnings released: CA$0.42 loss per share (vs CA$0.027 profit in 1Q 2023)

IM Cannabis Corp. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings: EPS misses analyst expectations

IM Cannabis Corp. to Report Fiscal Year 2023 Results on Mar 28, 2024

Kadimastem Ltd (TASE:KDST) entered into a non-binding term sheet to acquire IM Cannabis Corp. (CNSX:IMCC) in reverse merger transaction.

New major risk - Share price stability

IM Cannabis Announces Receipt of Court Action

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

IM Cannabis Corp. to Report Q3, 2023 Results on Nov 13, 2023

IM Cannabis Corp. Announces Executive Changes

IM Cannabis Corp., Annual General Meeting, Dec 06, 2023

IM Cannabis Corp. Announces Departure of Itay Vago as CFO

New major risk - Market cap size

IM Cannabis Corp. to Report Q2, 2023 Results on Aug 14, 2023

New major risk - Financial position

IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement

IM Cannabis Corp. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

IM Cannabis Corp. Commences Exit of Canadian Cannabis Market to Focus its Resources on Pursuing Growth Opportunities in Israel, Germany and Europe

IM Cannabis Corp. to Report Q3, 2022 Results on Nov 14, 2022

High number of new directors

High number of new directors

CEO & Director recently bought US$118k worth of stock

Executive Chairman recently bought US$80k worth of stock

IM Cannabis Corp. Announces Board Changes

IM Cannabis Shareholder Rafael Gabay raises stake

IM Cannabis Corp. announced that it expects to receive $5 million in funding

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

IM Cannabis GAAP EPS of -C$0.30, revenue of C$23.8M

IM Cannabis Corp., Annual General Meeting, Oct 20, 2022

IM Cannabis Corp. to Report Q2, 2022 Results on Aug 15, 2022

IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

IM Cannabis receives non-compliance notification from Nasdaq for minimum bid price requirement

First quarter 2022 earnings: EPS and revenues miss analyst expectations

IM Cannabis Corp. Provides Preliminary Unaudited Revenue Guidance for the Second Quarter 2022

IM Cannabis Corp. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

CEO & Director recently bought US$336k worth of stock

Full year 2021 earnings: EPS and revenues exceed analyst expectations

IM Cannabis Corp. Provides Earnings Guidance for Fourth Quarter of 2021 and Full Year 2022

Third quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.017 profit in 3Q 2020)

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Insider recently sold US$60k worth of stock

Second quarter 2021 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in 2Q 2020)

cbdMD And IM Cannabis Partner To Sell CBD Products In Israeli Markets

IM Cannabis Corp. Unveils Proprietary Data from A Clinical Survey Evaluating Medicinal Cannabis Therapy

First quarter 2021 earnings released: EPS CA$0.11 (vs CA$0.011 loss in 1Q 2020)

IM Cannabis Corp. Provides Earnings Guidance for the Second Quarter of 2021

IM Cannabis proposes public offering of securities

IM Cannabis acquires Israel's largest retail and online pharmacy business from Panaxia

Full year 2020 earnings released: CA$0.74 loss per share (vs CA$0.23 loss in FY 2019)

IM Cannabis Corp. Provides Preliminary Earnings Guidance for the First Quarter and Second Quarter of 2021

IM Cannabis Corp. (CNSX:IMCC) completed the acquisition of Trichome Financial Corp. (CNSX:TFC) from Cresco Labs Inc., Opaskawayak Cree Nation and others.